Greater Minneapolis-St. Paul Area
For over 30 years, my mission has been to bridge the gap between biological complexity and actionable medical data. My career has centered on a single conviction: that the most perfect diagnostic record of human health already exists within the immune system—we simply needed the right platform to decode it. As the CEO of Immune IQ, I am leading the commercialization of Immune Reveal™, a first-of-its-kind diagnostic category: Comprehensive Disease Identification. By combining nurse-operable point-of-care (POC) hardware with AI-native immune signatures, we are moving medicine from reactive crisis management to proactive precision defense. My journey of "Solving the Impossible": Pioneering POC Diagnostics: Co-founded Diametrics Medical (NASDAQ listed), which challenged the industry consensus by delivering lab-quality blood-gas results in 2 minutes at the bedside. This work laid the foundation for systems currently generating over $1B in annual revenue. Architecting Scalable AI: Founded MultiLogic, where we developed some of the first web-based AI platforms for global institutions like JPMorgan and Merrill Lynch. This experience taught us a critical lesson: AI is only as reliable as the data infrastructure feeding it. The Birth of Immune IQ: At Ativa Medical, we spent over a decade perfecting a standardized "blood data engine". We retired the foundational scientific and engineering risks through validation at Massachusetts General Hospital, proving that our platform matches lab-based accuracy while eliminating the hospital-to-hospital variability that typically renders AI unreliable. What We Are Building Now: Today, Immune IQ is in its commercial execution phase, headquartered in the Minneapolis–St. Paul medtech corridor. With a team that has built and scaled category-defining companies before, we are advancing toward FDA clearance and a global launch of a platform that identifies multiple disease states—often before symptoms appear. I am always looking to connect with strategic partners, institutional investors, and fellow innovators who share a vision for a world where time no longer stands between life and death.
www.immuneiq.com
Key responsibilities include fundraising (angel, venture capital, strategic), strategy, marketing and POCT technology development including flow cytometry, colorimetric, electrochemical, and imaging.
Ativa, in conjunction with Honeywell, LabCorp and several other Global Fortune 100 companies, has quietly developed a revolutionary fluid processing engine that allows it’s MicroLAB to uniquely perform the full analytical processes utilized in large lab blood analyzers entirely on a low-cost disposable card. The significance of this breakthrough is that it will enable almost all of the test panels that form the backbone of blood testing to be performed by nurses at the point of care. For the first time small/midsized clinics will be able to do real-time testing themselves rather than waiting for a day or more for the traditional blood send-out process (approximately $150B per year). Also, this capability will significant expand the reach of AI-based medicine, telemedicine and retail clinics which are all currently constrained because crucial blood testing data in not available. A device that enables comprehensive blood testing to be done on-site by nurses and others has the potential to radically transform the healthcare delivery landscape as we know it today. Key responsibilities included organizational management, fundraising (angel, venture capital, strategic), strategy, marketing and POCT technology development including flow cytometry, colorimetric, electrochemical, and imaging.
MultiLogic Inc. (ML) - In the 1970's, 80's and 90's artificial intelligence (AI) had much promise and fanfare however it was legendary for it’s resistance to commercialization. Although rule-based engines i.e. Expert Systems, a fundamental class of AI, were capable of defeating world chess champions there were few, if any, deep commercial applications. Expert Systems were widely viewed as a failed technology. ML utilized a systems-centric approach to manage the extensive cross-functional complexities (AI technology, market fragmentation, regulatory issues and market perception) to ultimately find a formula for successful commercialization of Expert Systems technology. The largest Wall Street firms (Citibank/SalomonSmithBarney, JPMorganChase, and Merrill Lynch) adopted ML's systems along with IT companies (HP, PeopleSoft). HP selected ML as a strategic partner in E-intelligence.
• Diametrics Medical Inc. (DMI) – The slow response time (~25 minutes) for blood gas (pO2, pCO2 and pH) measurements, one of the most critical tests in medicine, was a well known healthcare problem. Because of its importance, several companies spent cumulatively about a third of a billion dollars unsuccessfully to resolve this issue. The web of interactions between diverse chemistries, biomolecules, electronics and software defied both development and manufacturing efforts. DMI utilized the power of several systems methodologies to meld the distinct technologies and enable the functionalities of a $25,000 instrument to be duplicated by a one inch hybrid chip. The outcome was a device capable of giving crucial information to physicians within 2 minutes in life-and-death situations. DMI went public on NASDAQ and was identified by Deloitte & Touche as one of the fastest growing medical technology companies in the nation, and the fastest in Minnesota.
David Deetz was hired by PPG to create an offsite biomedical sensors skunkworks project for PPG. It was initially formed in La Jolla, CA and the focus was to create the world’s first portable blood gas system. The group won PPG’s highest award and was ultimately acquired by Radiometer/Danaher. The core technology we developed is the basis for their ABL 80/90 series of analyzers which now exceeds a billion dollars of sales annually.